Absolute quantification for clinical-resistant BCR-ABL mutants from Chronic myeloid leukemia (CML)

机译：慢性骨髓白血病（CML）的临床抗性BCR-ABL突变体的绝对量化

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

To determine the dynamic range of this quantitative assay, we performed the expression levels of proteins which is the exact copy numbers of the mutated Bcr-Abl protein from the CML cell line, BaF3. AQUA strategy is a sensitive method of quantification for Bcr-Abl mutations. Limits of detection (S/N>2) and limits of quantification (S/N>10) for these peptides were found to be 2 femtomoles and 10 femtomoles, respectively. The use of AQUA method may be applicable to monitor dynamic changes of the target proteins before and during therapy with tyrosine kinase inhibotor.

机译：为了确定该定量测定的动态范围，我们进行了来自CML细胞系BAF3的突变BCR-ABL蛋白的精确拷贝数的蛋白质的表达水平。 AQUA策略是对BCR-ABL突变的敏感方法。发现这些肽的检测限（S / N> 2）和定量限制（S / N> 10）分别为2毫小菌和10毫微微摩尔。 Aqua方法的使用可能适用于用酪氨酸激酶抑制剂治疗前后的目标蛋白的动态变化。

著录项

来源
《ASMS Conference on Mass Spectrometry and Allied Topics》|2008年||共1页
会议地点
作者
Jung Ok Park; Gum Yong Kang; Sun Kyu Choi; Dong Wook Kim; Young Hwan Kim; Kwang Pyo Kim;
展开▼
作者单位

展开▼
会议组织
原文格式 PDF
正文语种
中图分类 TB994.5-53;
关键词

相似文献

外文文献
中文文献
专利

1. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) [J] . Wu Jiaxin, Wang Aoli, Li Xixiang, Cancer biology & therapy . 2019,第4a6期

机译：对慢性髓性白血病（CML）的新型高效和选择性II天然和耐药V299L突变体BCR-ABL-039）的发现和表征
2. Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir [J] . Niyaz A Azad, Zafar A Shah, Arshad A Pandith, Asian Pacific Journal of Cancer Prevention . 2018,第6期

机译：伊马替尼治疗的慢性粒细胞白血病（CML）中BCR-ABL融合转录变体的预后意义。克什米尔CML患者的同类研究首次
3. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lympoblastic Leukemia wit [J] . B. J. Druker, M. Talpaz, D. J. Resta, Chemtracts . 2001,第13期

机译：BCR-ABL酪氨酸激酶特异性抑制剂在慢性粒细胞白血病中的功效和安全性BCR-ABL酪氨酸激酶特异性抑制剂在慢性粒细胞白血病和急性淋巴细胞白血病机智的爆发危机中的活性
4. Absolute quantification for clinical-resistant BCR-ABL mutants from Chronic myeloid leukemia (CML) [C] . Jung Ok Park, Gum Yong Kang, Sun Kyu Choi, ASMS Conference on Mass Spectrometry and Allied Topics . 2008

机译：慢性骨髓白血病（CML）的临床抗性BCR-ABL突变体的绝对量化
5. Characterization of hemopoietic stem cells in chronic myeloid leukemia (CML). [D] . Udomsakdi, Chirayu. 1992

机译：慢性粒细胞白血病（CML）中造血干细胞的特征。
6. Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) [O] . Jiaxin Wu, Aoli Wang, Xixiang Li, 2019

机译：发现和表征一种新型的强效和选择性II型天然和耐药V299L突变型BCR-ABL抑制剂（CHMFL-ABL-039）用于治疗慢性粒细胞白血病（CML）
7. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML) [O] . Feiyang Liu, Beilei Wang, Qiang Wang, 2016

机译：用于慢性髓性白血病（CML）的新型有效型II天然和突变体BCR-ABL抑制剂（CHMFL-074）的发现和表征

Absolute quantification for clinical-resistant BCR-ABL mutants from Chronic myeloid leukemia (CML)

摘要

著录项

相似文献

相关主题

期刊订阅